H E Kvalem1, U C Nygaard1, K C Lødrup Carlsen2, K H Carlsen2, L S Haug1, B Granum3. 1. Norwegian Institute of Public Health, Division of Infection Control and Environmental Health, Oslo, Norway. 2. Institute for Clinical Medicine, University of Oslo, Norway; Department of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway. 3. Norwegian Institute of Public Health, Division of Infection Control and Environmental Health, Oslo, Norway. Electronic address: berit.granum@fhi.no.
Abstract
INTRODUCTION: Exposure to perfluoroalkyl substances (PFASs) has been inconsistently associated with asthma, allergic diseases and airways infections in early childhood. The aim of the study was, therefore, to investigate the effect of childhood exposure to PFASs on asthma and allergy related outcomes and on airways infections before and during puberty using the prospective birth cohort Environment and Childhood Asthma (ECA) Study. Aspects of gender, exposure period and study design (cross-sectional and longitudinal) were also taken into consideration. MATERIAL AND METHODS: Included in the study was 378 participants with PFAS measurements at age 10 years and follow-up data at ages 10 years (cross sectional data) and 16 years (longitudinal data). Eight PFASs with at least 70% of measurements above the limit of quantification (LOQ) in the child's serum were included in the present study: perfluoroheptanoate (PFHpA), perfluorooctanoate (PFOA), perfluourononanoate (PFNA), perfluorodecanoate (PFDA), perfluoroundecanoate (PFUnDA), perfluorohexane sulfonate (PFHxS), perfluoroheptane sulfonate (PFHpS) and perfluorooctane sulfonate (PFOS). The PFAS levels were converted into interquartile range (IQR). In addition, perfluorooctane sulfonamide (PFOSA) detected in 60% of the samples, was recoded into "not detected /detected". Binomial, multinomial and linear regression were used, followed by Bonferroni adjustment to correct for multiple comparisons. Sensitivity analyses evaluating the effect of extreme PFAS values and gender were performed. RESULTS: In the cross sectional data at 10 years a positive statistically significant association was seen between PFHpA and asthma in girls. In the longitudinal data, PFNA, PFDA and PFUnDA were inversely associated with atopic dermatitis (AD) in girls and with PFHxS in all participants and in boys. Further, PFNA and PFHpS were positively associated with rhinitis in girls and with PFOA in all participants. There seems to be a suggestive pattern of increased risk of allergic sensitisation in all participants and a decreased risk in boys, but due to different results in main and sensitivity analyses these findings should be interpreted with caution. No associations were found between PFASs and lung function. For airways infections and longitudinal data, PFDA was inversely associated with common cold, while positive association was found for PFHpA, PFOA, PFHpS and PFOS and lower respiratory tract infections (LRTI). DISCUSSION AND CONCLUSION: Our results lend further support for an immunosuppressive effect of PFASs on AD and LRTI. Gender seems to be important for some exposure-health associations. No clear pattern in exposure-health associations was observed with regard to exposure period or study design, with the exception of asthma where significant findings have mostly been reported in cross-sectional studies.
INTRODUCTION: Exposure to perfluoroalkyl substances (PFASs) has been inconsistently associated with asthma, allergic diseases and airways infections in early childhood. The aim of the study was, therefore, to investigate the effect of childhood exposure to PFASs on asthma and allergy related outcomes and on airways infections before and during puberty using the prospective birth cohort Environment and Childhood Asthma (ECA) Study. Aspects of gender, exposure period and study design (cross-sectional and longitudinal) were also taken into consideration. MATERIAL AND METHODS: Included in the study was 378 participants with PFAS measurements at age 10 years and follow-up data at ages 10 years (cross sectional data) and 16 years (longitudinal data). Eight PFASs with at least 70% of measurements above the limit of quantification (LOQ) in the child's serum were included in the present study: perfluoroheptanoate (PFHpA), perfluorooctanoate (PFOA), perfluourononanoate (PFNA), perfluorodecanoate (PFDA), perfluoroundecanoate (PFUnDA), perfluorohexane sulfonate (PFHxS), perfluoroheptane sulfonate (PFHpS) and perfluorooctane sulfonate (PFOS). The PFAS levels were converted into interquartile range (IQR). In addition, perfluorooctane sulfonamide (PFOSA) detected in 60% of the samples, was recoded into "not detected /detected". Binomial, multinomial and linear regression were used, followed by Bonferroni adjustment to correct for multiple comparisons. Sensitivity analyses evaluating the effect of extreme PFAS values and gender were performed. RESULTS: In the cross sectional data at 10 years a positive statistically significant association was seen between PFHpA and asthma in girls. In the longitudinal data, PFNA, PFDA and PFUnDA were inversely associated with atopic dermatitis (AD) in girls and with PFHxS in all participants and in boys. Further, PFNA and PFHpS were positively associated with rhinitis in girls and with PFOA in all participants. There seems to be a suggestive pattern of increased risk of allergic sensitisation in all participants and a decreased risk in boys, but due to different results in main and sensitivity analyses these findings should be interpreted with caution. No associations were found between PFASs and lung function. For airways infections and longitudinal data, PFDA was inversely associated with common cold, while positive association was found for PFHpA, PFOA, PFHpS and PFOS and lower respiratory tract infections (LRTI). DISCUSSION AND CONCLUSION: Our results lend further support for an immunosuppressive effect of PFASs on AD and LRTI. Gender seems to be important for some exposure-health associations. No clear pattern in exposure-health associations was observed with regard to exposure period or study design, with the exception of asthma where significant findings have mostly been reported in cross-sectional studies.
Authors: Tina Savvaides; Jeremy P Koelmel; Yakun Zhou; Elizabeth Z Lin; Paul Stelben; Juan J Aristizabal-Henao; John A Bowden; Krystal J Godri Pollitt Journal: Curr Environ Health Rep Date: 2022-01-05
Authors: Medina S Jackson-Browne; Melissa Eliot; Marisa Patti; Adam J Spanier; Joseph M Braun Journal: Int J Hyg Environ Health Date: 2020-05-30 Impact factor: 5.840
Authors: Tiina Mattila; Tiina Santonen; Helle Raun Andersen; Andromachi Katsonouri; Tamás Szigeti; Maria Uhl; Wojciech Wąsowicz; Rosa Lange; Beatrice Bocca; Flavia Ruggieri; Marike Kolossa-Gehring; Denis A Sarigiannis; Hanna Tolonen Journal: Int J Environ Res Public Health Date: 2021-02-01 Impact factor: 3.390
Authors: Haley von Holst; Pratibha Nayak; Zygmunt Dembek; Stephanie Buehler; Diana Echeverria; Dawn Fallacara; Lisa John Journal: Heliyon Date: 2021-10-12
Authors: Suzanne E Fenton; Alan Ducatman; Alan Boobis; Jamie C DeWitt; Christopher Lau; Carla Ng; James S Smith; Stephen M Roberts Journal: Environ Toxicol Chem Date: 2020-12-07 Impact factor: 4.218
Authors: Dolores Catelan; Annibale Biggeri; Francesca Russo; Dario Gregori; Gisella Pitter; Filippo Da Re; Tony Fletcher; Cristina Canova Journal: Int J Environ Res Public Health Date: 2021-03-08 Impact factor: 3.390